Editing Survival Statistics (section)

== How Has Immunotherapy Changed Survival Outcomes? ==

The approval of nivolumab plus ipilimumab in 2020 marked the first new systemic treatment for mesothelioma in over 15 years and has substantially improved survival expectations.<ref>[https://dandell.com/mesothelioma-lawyer/ Nationwide Mesothelioma Lawyers], Danziger & De Llano</ref>

The CheckMate 743 trial, with 3-year follow-up data representing the most mature efficacy analysis available, demonstrated median overall survival of 18.1 months with immunotherapy versus 14.1 months with chemotherapy (hazard ratio 0.73).<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref> Three-year survival rates reached 23% versus 15%, with 3-year progression-free survival of 14% versus just 1% for chemotherapy.

Critically, 28% of patients who responded to immunotherapy maintained their response at 3 years, compared to 0% in the chemotherapy group—demonstrating the potential for durable disease control in selected patients.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/treatment/ Mesothelioma Treatment Guide], Mesothelioma Lawyer Center</ref>

New molecular analyses have identified predictive biomarkers for immunotherapy response. Patients with triple mutations (BAP1/CDKN2A/CDKN2B) plus PD-L1 positivity achieved median survival of 15.8 months versus 9.4 months with chemotherapy alone.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>

{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; color:#333333;" | "The immunotherapy revolution has fundamentally changed how we approach mesothelioma cases. Patients now have treatment options that weren't available even five years ago, which affects both their medical decisions and their legal strategy."
|-
| style="padding:5px 25px 20px; text-align:right; color:#333333;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
|}